This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

45/100

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Cognitive tests and assessment

Topic: Amyloid, tau and blood-test diagnosis

Introduction A novel amyloid β (Aβ) synthetic peptide vaccine (UB-311) has been evaluated in a first-in-human trial with patients of mild-to-moderate Alzheimer's disease. We describe translational research covering vaccine design, preclinical characterization, and phase-I clinical trial with supportive outcome that advances UB-311 into an ongoing phase-II trial. Methods UB-311 is constructed with two synthetic Aβ 1-14 -targeting peptides (B-cell epitope), each linked to different helper T-cell peptide epitopes (UBITh ® ) and formulated in a Th2-biased delivery system.

Key findings

We describe translational research covering vaccine design, preclinical characterization, and phase-I clinical trial with supportive outcome that advances UB-311 into an ongoing phase-II trial.
Methods UB-311 is constructed with two synthetic Aβ 1-14 -targeting peptides (B-cell epitope), each linked to different helper T-cell peptide epitopes (UBITh ® ) and formulated in a Th2-biased delivery system.
The hAPP751 transgenic mouse model was used to perform the proof-of-concept study.
Baboons and macaques were used for preclinical safety, tolerability, and immunogenicity evaluation.

Why it matters

This report describes the design, preclinical testing, and phase-I trial of UB-311, an amyloid beta peptide vaccine for mild-to-moderate Alzheimer's disease, which is advancing into a phase-II trial. It is early-stage vaccine development and does not establish that UB-311 treats, cures, or prevents Alzheimer's disease.

Study details

Evidence strengthLow

How this study scored 45/100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.))
Journal's citation record	1 / 4	Alzheimer s & Dementia Translational Research & Clinical Interventions: journal h-index 84 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	2 / 5	2017 — within 10 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 149 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	13.5 citations a year over 11 year(s) since 2017
Impact for its field and year	3 / 6	Cited 7.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 5 other studies in this library
Still being cited	2 / 4	Cited 48 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Paul Frohna: h-index 20 (OpenAlex, whole career)
Institution's track record	0 / 3	National Taiwan University Hospital: institution h-index 509 (OpenAlex)
Multi-centre collaboration	1 / 3	OpenAlex lists 3 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 29067332)
Free to read	2 / 2	Free to read
Total	45 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Wang, C. Y., Wang, P. N., Chiu, M. J., Finstad, C. L., Lin, F., Lynn, S., et al. (2017). UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1016/j.trci.2017.03.005

Vancouver

Wang CY, Wang PN, Chiu MJ, Finstad CL, Lin F, Lynn S, et al. UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). 2017. doi:10.1016/j.trci.2017.03.005. PMID: 29067332.

BibTeX

@article{wang2017-29067332,
  author  = {Wang, C. Y. and Wang, P. N. and Chiu, M. J. and Finstad, C. L. and Lin, F. and Lynn, S. and Tai, Y. H. and De Fang, X. and others},
  title   = {{UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2017},
  doi     = {10.1016/j.trci.2017.03.005},
  pmid    = {29067332},
  url     = {https://doi.org/10.1016/j.trci.2017.03.005}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Cognitive tests and assessment

Also tagged “double-blind”

783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →